Summary："ADMA Biologics Investors Warned: Urgent Deadline to Join Securities Fraud Lawsuit Looms"NEW YORK, J

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"ADMA Biologics Investors Warned: Urgent Deadline to Join Securities Fraud Lawsuit Looms"

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Investors who have purchased securities of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) are being reminded by Kirby McInerney LLP that a critical deadline is approaching to participate in a securities fraud class action lawsuit. The law firm is urging those who have suffered financial losses to contact Lauren Molinaro at investigations@kmllp.com to discuss their options.

Key developments have raised concerns among investors regarding the Company's alleged misrepresentations and omissions about its business operations and financial health. The lawsuit asserts that ADMA Biologics made false and misleading statements, potentially violating federal securities laws. As the investigation unfolds, investors are becoming increasingly aware of the potential risks associated with their investments in the Company.

The biopharmaceutical industry, in which ADMA Biologics operates, is highly competitive and subject to rigorous regulatory scrutiny. The Company's focus on developing and commercializing specialty plasma-derived biologics has garnered significant attention. However, the ongoing lawsuit may impact investor confidence and the Company's market valuation. Industry analysts are closely monitoring the situation, as the outcome may have far-reaching implications for the sector.

As the deadline to join the securities fraud lawsuit draws near, investors are advised to carefully consider their options. The outcome of the lawsuit may result in potential recoveries for eligible investors. Moreover, the case may shed light on the Company's governance and risk management practices, influencing investor perceptions and the Company's long-term prospects.

In conclusion, the looming deadline to participate in the securities fraud lawsuit against ADMA Biologics serves as a critical reminder for investors to assess their potential losses and take action. As the biopharmaceutical industry continues to evolve, the outcome of this case may have significant implications for companies operating in this space. Investors are encouraged to reach out to Kirby McInerney LLP to discuss their options and potential next steps in this developing story.